

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human MAVS in direct ELISAs.
Source	Monoclonal Mouse IgG _{2B} Clone # 981240
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human MAVS Arg37-Pro513 Accession # Q7Z434
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunohistochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Mitochondrial antiviral signaling protein (MAVS, also known as IPS-1, VISA, and CARDIF) is a ubiquitous, tail-anchored membrane protein inserted in the outer mitochondrial membrane (OMM), and is also found in the peroxisomal membrane and the mitochondrial associated membrane of the endoplasmic reticulum. Peroxisomal MAVS has been implicated in type II IFN-dependent antiviral response, while mitochondrial MAVS mediates longer lasting type I IFN dependent antiviral response. Mitochondrial reactive oxygen species (mROS) induce oligomerization of MAVS in the outer membrane plane of mitochondria to induce innate immunity to viral infection. MAVS undergoes RIG-I-like receptors (RLR)-induced formation of higher order structures ranging from dimers to prion-like aggregates that lead to the recruitment and activation of signaling proteins culminating in the activation of the transcription factors IRF-3 and NF-κB and transcription of IFNs

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.